admin | April 29, 2021
October 2, 2014
Shire Japan KK announced that the Japanese MHLW (Ministry of Health, Labour and Welfare) has approved AGRYLIN® (anagrelide hydrochloride) for the treatment of essential thrombocythemia. AGRYLIN went through clinical trials in response to a request from MHLW in May 2010 based on the results of its “Study Group on Unapproved and Off-Label Drugs of High Medical Need”. AGRYLIN has been designated as an orphan drug.